Compare · ALZN vs AVXL
ALZN vs AVXL
Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Anavex Life Sciences Corp. (AVXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ALZN focuses on Biotechnology: Pharmaceutical Preparations, while AVXL focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AVXL is the larger of the two at $86.2M, about 14.4x ALZN ($6.0M).
- AVXL has been more active in the news (7 items in the past 4 weeks vs 1 for ALZN).
- AVXL has more recent analyst coverage (6 ratings vs 1 for ALZN).
- Company
- Alzamend Neuro Inc.
- Anavex Life Sciences Corp.
- Price
- -
- -
- Market cap
- $6.0M
- $86.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 7
- Recent ratings
- 1
- 6
Alzamend Neuro Inc.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Latest ALZN
- Amendment: Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form RW filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- SEC Form 10-Q filed by Alzamend Neuro Inc.
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)
- SEC Form PRE 14A filed by Alzamend Neuro Inc.
- SEC Form S-1 filed by Alzamend Neuro Inc.
Latest AVXL
- Director Velden Claus Vander was granted 50,000 stock options (SEC Form 4)
- Director Donhauser Peter D.O. was granted 50,000 stock options (SEC Form 4)
- President and CEO Kellmeyer Terrie was granted 200,000 stock options (SEC Form 4)
- Director Paeger Axel was granted 50,000 stock options (SEC Form 4)
- Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors
- Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
- SEC Form 8-K filed by Anavex Life Sciences Corp.
- Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies